medical research and clinical trials rels 300 / nurs 330 30 october 2014
TRANSCRIPT
MEDICAL RESEARCH ANDCLINICAL TRIALS
Rels 300 / Nurs 330
30 October 2014
What is a clinical trial?
a research study designed to evaluate a new drug or medical therapy; e.g., compare a new drug or treatment with a commonly
used (older) drug or treatment; compare [a combination of a new drug + an older
drug] with [the older drug alone] compare different doses of a common drug, or
different doses of a newly developed drug
300/330 - appleby 2
What else do I need to know?• Interventional study – participants receive specific interventions
• Observational study – assess health outcomes in groups of
participants
• Adverse event – An unfavorable change in the health of a participant
• Serious adverse event – An adverse event that results in death, is life-
threatening, or incapacitating, or causes a congenital anomaly or birth
defect
• Placebo – A substance (or intervention) that does not contain active
ingredients
• Arm (or cohort) – A group or subgroup of participants
• Masking (or blinding) – Whether none, or one, or both parties involved
with the trial (such as the investigator or participant) know to which arm
a person has been assigned.
300/330 - appleby 3
4 Phases of clinical trials:Phase 1 clinical trials Studies designed to assess safety and tolerability–
Is this drug safe? a small group of healthy volunteers are given the drug to
see if there are safety issues or common side effects of a drug;
the healthy volunteers may be given various doses of the drug to see what dosages seem most tolerable;
different drug delivery methods may be tested;
sometimes, phase 1 trials are conducted on people for whom no standard treatment would be effective (can you think of an example of this?)
300/330 - appleby 4
Phase II clinical trialsStudies designed to test the clinical efficacy of the drug –
Does this drug work?people who have the relevant condition or disease take the new drug;
some healthy volunteers also participate in this phase;
larger groups are tested;continued testing for safety at different doses; initial assessments of efficacy are made.
300/330 - appleby 5
Phase III clinical trials
Studies designed to test the effectiveness of the new drug Is the new drug more effective than existing
treatments? much larger numbers of patients and healthy volunteers
are involved in studies; tests efficacy of the new drug to:
prolong life or improve quality of life; reduce the risk of disease recurrence; be effective with fewer or milder side effects.
test safety of the new drug
300/330 - appleby 6
Phase IV clinical trials
Studies conducted after both safety and efficacy have been established
Can this drug be used more effectively?
Very large group of study participants; long-term adverse effects are studied; dosage adjustments may be done to increase
effectiveness or reduce side effects; Can you think of a fairly recent phase IV study that
resulted in the removal of a drug from the market?
300/330 - appleby 7
Let’s design a study
The research question for this study will be: Do students who drink caffeinated beverages perform
better on final exams?
1. Design a phase I study for this research; what will a phase I study be able to establish?
2. Design a phase II study; what will a phase II study be designed to test?
3. Design a phase III study; what do you want to accomplish with a phase III study?
4. If caffeine has passed in phase III studies, how would you design a phase IV study of caffeine?
300/330 - appleby 8
Refine your research on caffeinated beverages
Phase I: Is this drug safe?
Phase II: Does this drug work?
Phase III: Is the new drug more effective than existing
treatments?
Phase IV: Can this drug be used more effectively? Is it useful for other conditions or purposes?
300/330 - appleby 9
EXAMPLE OF PLACEBO-CONTROLLED STUDYPhase 2, Interventional Study with Placebo
Title: Improvement of Subjective Well-Being by Ranolazine Among Chronic Stable
Coronary Artery Disease Patients
300/330 - appleby 10
Phase 2, Interventional Study with Placebo
Summary: double-blind, placebo-controlled, randomized, single-center study; 50 study participants, 18 or older, stable, have not had bypass surgery
Objective: to determine if ranolazine improves angina symptoms at 4 months compared with placebo among stable coronary artery disease patients
Week 1: one tablet (500 mg ranolazine or placebo) twice a day
Weeks 2 – 16: one tablet (1000 mg ranolazine or placebo) twice a day
Every week: phone call to assess well-being, adverse events
End of 4th month: assess frequency of symptoms and well-being using the Seattle Angina Questionnaire
Ethical analysis of placebo controlled studies
Why do researchers use placebo controlled studies?
What benefit do they provide for the clinical trial results?
What concerns do ethicists have about placebo controlled studies?
Are there potential patient risks in placebo studies?
300/330 - appleby 12
Canadian guidelines on Placebos
Therapeutic Products Directorate:
“new psychiatric drugs must be tested against placebo, and shown to be better”
Medical Research Council of Canada:
“[p]articular care must be taken … to ensure that the subject’s best interest is never sacrificed to that of the randomized study”
Tri-Council Policy Statement:
“the use of placebo controls in clinical trials is generally unacceptable when standard therapies or interventions are available”
300/330 - appleby 13
TCPS
TRI-COUNCIL POLICY STATEMENT:ETHICAL CONDUCT FOR RESEARCH INVOLVING HUMANS2ND EDITION, 2010http://pre.ethics.gc.ca/eng/policy-politique/initiatives/tcps2-eptc2/default/
300/330 - appleby 15
• Canadian Institutes Of Health Research (CIHR)• The Natural Sciences And Engineering Research Council
(NSERC) • The Social Sciences And Humanities Research Council (
SSHRC)
Interagency Advisory
Panel on Research Ethics (PRE)
300/330 - appleby 16
Respect for Human Dignity
Respect for human dignity requires that research involving humans be conducted in a manner that is sensitive to the inherent worth of all human beings and the respect and consideration that they are due.
In this Policy, respect for human dignity is expressed through three core principles:
1. Respect for Persons
2. Concern for Welfare
3. Justice
300/330 - appleby 17
Core Principles of the TCPS
1. Respect for persons• Respect for free and informed consent• Respect for vulnerable persons
2. Concern for welfare• Respect for privacy and confidentiality• The principle of Concern for welfare is applied by
• Balancing harms and benefits• Minimizing harm, and• Maximizing benefit
3. Justice• Respect for vulnerable persons
300/330 - appleby 18
1. Respect for Persons• Recognize the intrinsic value of human persons• Demonstrate respect for the person’s autonomy
• Seek free, informed and ongoing consent• Remove constraints of manipulation, coercion, lack of
knowledge• Assess a person’s capacity to make his or her own
decision
• If lacking capacity• Seek consent from someone authorized to make decisions on his or her behalf
• Seek verbal assent from person
300/330 - appleby 19
2. Concern for Welfare
• A person’s welfare includes:• Physical, mental and spiritual health• Physical, economic and social circumstances
(determinants of health)• Welfare is enhanced by respect for privacy and confidentiality
• Concern for welfare is demonstrated by maximizing benefits, minimizing risks and harms, and ensuring a favourable balance of harms and benefits
300/330 - appleby 20
3. Justice
• Ethical obligation to treat people fairly and equitably• Demonstrate equal respect and concern• Distribute the benefits and burdens of participating in
research – no one bears the burdens without access to the potential benefits
• Respect for vulnerability:• Recognition of vulnerability or vulnerable circumstances – children,
elderly, women, mentally incompetent, racial minorities, institutionalized people
• Equitable inclusion & exclusion criteria• Be mindful of power imbalances – minimize potential
harms
Tri-Council Policy Statementhttp://www.pre.ethics.gc.ca/eng/policy-politique/initiatives/tcps2-eptc2/Default/
Placebo-Controlled Trials
Article 11.2
(a) A new therapy or intervention should generally be tested against an established effective therapy.
300/330 - appleby 21
(b) As with all alternative choices of a control, a placebo control is ethically acceptable in a randomized controlled clinical trial only if:
its use is scientifically and methodologically sound in establishing the efficacy or safety of the test therapy or intervention; and
it does not compromise the safety or health of participants; and
the researcher articulates to the REB a compelling scientific justification for the use of the placebo control.
300/330 - appleby 22
(c) For clinical trials involving a placebo control, the researcher and the REB shall ensure the general principles of consent are respected and that participants or their authorized third parties are specifically informed
about any therapy that will be withdrawn or withheld for purposes of the research; and
of the anticipated consequences of withdrawing or withholding the therapy.
300/330 - appleby 23
“Clinical Equipoise”Benjamin Freedman
“at the start of an RCT there must exist honest, professional disagreement in the community of expert practitioners as to the preferred treatment”
“Clinical equipoise means a genuine uncertainty exists on the part of the relevant expert community about what therapy or therapies are most effective for a given condition. This uncertainty necessitates the conduct of research to determine the comparative therapeutic merits of existing interventions.” TCPS
(text p.108-9)
300/330 - appleby 24
TCPS: 5 conditions for ethical use of a placebo in a study1. there are no established effective therapies;
2. there is substantial doubt within the relevant expert community regarding the benefit of available therapies;
3. patients may be resistant to the available therapies;
4. the trial involves adding a new investigational therapy to established effective therapies:• established effective therapy plus new therapy• established effective therapy plus placebo;
5. patients have provided an informed refusal of established effective therapy, and withholding such therapy will not cause serious or irreversible harm.
300/330 - appleby 25
Phase 2, Interventional Study with Placebo
Title: Improvement of Subjective Well-Being by Ranolazine Among Chronic Stable Coronary Artery Disease Patients
Summary: double-blind, placebo-controlled, randomized, single-center study; 50 study participants, 18 or older, stable, have not had bypass surgery
Objective: to determine if ranolazine improves angina symptoms at 4 months compared with placebo among stable coronary artery disease patients
Week 1: one tablet (500 mg ranolazine or placebo) twice a day
Weeks 2 – 16: one tablet (1000 mg ranolazine or placebo) twice a day
Every week: phone call to assess well-being, adverse events, etc.
End of 4th month: assess frequency of symptoms and well-being using the Seattle Angina Questionnaire
Would this study pass the TCPS 5 conditions for a placebo study?
Any Questions?
300/330 - appleby 27
Ebola Vaccine Research2 vaccines currently being tested:
1. VSV-ZEBOV – Public Health Agency of Canada• Phase 1; 39 healthy adults, 18 to 65
• 3 groups; 10 in each will receive different doses of the trial vaccine, 3 will receive a placebo; staggered entry with escalating doses for safety
• Compare the immune responses at different dosages
2. ChAd3 – US National Institute of Allergy and Infectious Diseases
• Phase 1; healthy adults, 18 to 65; 10 will receive trial vaccine, 3 will receive placebo
• 2 doses, 28 days apart; compare immune responses
Researchers hope to start Phase 2 studies in January 2015
300/330 - appleby 28
CENTRAL ETHICAL QUESTION RAISED:Is it unethical to give volunteers a placebo if they’re at risk for contact with a disease that has a very high fatality rate?
Phase 1 studies will move forward quickly with healthy volunteers (now underway).
It is likely that Phase 2 studies will involve larger numbers of people, and perhaps health care providers.
Health care workers will definitely be the first to receive a vaccine if results are positive.
300/330 - appleby 29